Fixing the Preclinical Foundation:
Poor Predictions to Patient Precision

Fibrotic diseases are driven by a complex interplay of genetic predisposition, environmental triggers, and cellular signaling across epithelial, stromal, and immune compartments. Yet most preclinical models, including animal systems and conventional epithelial organoids, fail to capture this multicellular interaction or the patient-specific heterogeneity that underlies disease pathogenesis. This disconnect contributes to poor translational predictability and high rates of late-stage clinical trial failure.
With the FDA moving to phase out animal testing requirements for preclinical studies, Caleo Bio's technology is uniquely positioned to lead the shift toward patient-first, human-relevant preclinical research.